ASAH2B: Potential Drug Target and Biomarker (G653308)

Target Name: ASAH2B

NCBI ID: G653308

ASAH2B

ASAH2B: Potential Drug Target and Biomarker

ASAH2B (ASAH2B), also known as S100A6, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the A-type hydrolipid transmembrane protein (A-HSP) family , which is characterized by the presence of a hydrophobic domain and a hydrophilic tail. The A-HSPs are involved in various cellular processes, including inflammation, stress responses, and signaling pathways.

The discovery and characterization of ASAH2B

The study of ASAH2B was first reported by Nimmerjahn et al. in 2004. They identified a protein that was expressed in the brain and Kendrog's cardiomyocytes, and they named it ASAH2B. Since then, several studies have confirmed its presence in various tissues and cell types.

Function and localization

ASAH2B is involved in various physiological processes in the body, including the regulation of inflammation, stress responses, and signaling pathways. It is a potent modifier of the classic NF-kappa-B signaling pathway, which is a central mediator of inflammation and stress responses.

ASAH2B functions as a negative regulator of the NF-kappa-B pathway. It can inhibit the activity of the NF-kappa-B enzyme, which is responsible for generating pro-inflammatory cytokines. This means that when ASAH2B is present in a cell, it can help to reduce the level of inflammation and stress responses in the cell.

In addition to its role in the NF-kappa-B pathway, ASAH2B is also involved in the regulation of cell adhesion and migration. It is a strong negative regulator of the integrin/CD73 signaling pathway, which is involved in the regulation of cell adhesion and migration. migration. This means that when ASAH2B is present in a cell, it can help to prevent cell adhesion and migration, which is important for the proper functioning of tissues and organs.

ASAH2B is also involved in the regulation of cellular signaling pathways. It is a negative regulator of the TGF-β pathway, which is involved in cell growth, differentiation, and survival. This means that when ASAH2B is present in a cell, it can help to prevent the excessive growth and survival of the cell, which is important for maintaining tissue homeostasis.

Drug targeting and biomarker potential

ASAH2B is a potential drug target because of its involvement in various cellular processes that are important for human health. Several studies have suggested that blocking ASAH2B may have therapeutic benefits for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

For example, several studies have suggested that inhibiting ASAH2B may be an effective way to treat cancer. ASAH2B has been shown to be involved in the regulation of cell cycle progression, which is important for the development and progression of cancer. In addition, ASAH2B has has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This means that inhibiting ASAH2B may be an effective way to target cancer cells that are involved in angiogenesis.

ASAH2B has also been suggested as a potential biomarker for several diseases, including cancer. The expression of ASAH2B has been shown to be involved in the regulation of various cellular processes that are important for human health. This suggests that ASAH2B may be a useful biomarker for diseases that are characterized by abnormal cellular processes, such as cancer.

Conclusion

ASAH2B is a protein that is expressed in various tissues of the body and is involved in various physiological processes

Protein Name: N-acylsphingosine Amidohydrolase 2B

The "ASAH2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASAH2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets